How GLP-1 Medications Will Transform the Food Industry in Finland
A look at the GLP-1 undercurrents reshaping consumer health, food, and brand strategy — and what they mean for Finnish food and beverage leaders.
- Why thirty years of reformulation never bent the obesity curve — and what did
- The consumer-patient: 45 to 65, paying for therapy herself, guided by Reddit rather than a care pathway
- Which Finnish categories are exposed, and where dairy, oats, fish and berries already meet the specification
Get the deck
Enter your details and we'll email you the slides right away.
Want more like this? There's an optional newsletter opt-in on the form for occasional insights from S2B Group. Unsubscribe at any time.
"Nearly 30 years at the intersection of nutrition science and food strategy led me to one conclusion: GLP-1 is the most consequential disruption this industry has faced. This presentation makes the case for why Finland's position today is an advantage, and what food leaders here need to do with it."
— Maha Tahiri, Ph.D. · CEO & Co-Founder, S2B Group
Ready to shape what can be?
Book a strategy session and see how S2B can help you turn these undercurrents into a competitive advantage for your brand.
Book a 30-minute meeting